Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 3—March 2013
Research

Treatment Outcomes for Extensively Drug-Resistant Tuberculosis and HIV Co-infection

Max R. O’DonnellComments to Author , Nesri Padayatchi, Charlotte Kvasnovsky, Lise Werner, Iqbal Master, and C. Robert Horsburgh
Author affiliations: Author affiliations: Albert Einstein College of Medicine, Bronx, New York, USA (M.R. O’Donnell); Centre for AIDS Programme of Research in South Africa, Durban, South Africa (M.R. O’Donnell, N. Padayatchi, L. Werner); University of Maryland School of Medicine, Baltimore, Maryland, USA (C. Kvasnovsky); King George V Hospital, Sydenham, South Africa (I. Master); Boston University School of Public Health, Boston, Massachusetts, USA (C.R. Horsburgh, Jr.); Boston University School of Medicine, Boston (C.R. Horsburgh, Jr.)

Main Article

Table 3

Predictors of 49 deaths at 24 months of treatment for 114 HIV-positive and HIV-negative XDR TB patients, KwaZulu-Natal Province, South Africa*

Predictor No. died/total no. (%) Univariate analysis
 Multivariate analysis†
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Sex
F 27/65 (41.5) 0.88 (0.50–1.54) 0.6484 0.95 (0.51–1.77) 0.8611
M
 22/49 (44.9)
 1.0 (referent)
 NA
1.0 (referent)
 NA
Age, y
<36 25/58 (43.1) 1.03 (0.59–1.80) 0.9285 NA NA
>36
 24/56 (42.9)
 1.0 (referent)
 NA
NA
 NA
Previous TB treatment‡
Yes 38/92 (41.3) 1.47 (0.53–4.13) 0.4614 1.28 (0.45–3.65) 0.6391
No 4/15 (26.7) 1.0 (referent) NA 1.0 (referent) NA
Unknown
 7/7 (100)
 NA
 NA
NA
 NA
Initial sputum smear result
Positive 30/67 (44.8) 1.05 (0.59–1.86) 0.8704 NA NA
Negative
 19/47 (40.4)
 1.0 (referent)
 NA
NA
 NA
HIV status‡
Positive 36/82 (43.9) 1.14 (0.58–2.25) 0.6971 1.30 (0.61–2.78) 0.4966
Negative 11/25 (44.0) 1.0 (referent) NA 1.0 (referent)
Unknown
 2/7 (28.6)
 NA
 NA
NA
 NA
Adverse event
Yes 23/52 (44.2) 1.02 (0.58–1.79) 0.9420 NA NA
No 26/62 (41.9) 1.0 (referent) NA NA NA

*XDR TB, extensively drug-resistant tuberculosis; NA, not applicable.
†Significant variables or variables that caused >10% change in the bivariate hazard ratio were included in the multivariate model.
‡Patients whose HIV status or previous TB treatment history was unknown were excluded from analyses.

Main Article

Page created: March 21, 2013
Page updated: March 21, 2013
Page reviewed: March 21, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external